Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth
Abbott leads in absolute revenue, but Intuitive Surgical's growth rate tells a different story over the past eight quarters.
Overview
Abbott Laboratories (NYSE:ABT) primarily generates its revenue by researching, developing, manufacturing, and distributing a diverse portfolio of medical devices, diagnostic test systems, nutritional formulas, and generic pharmaceutical products across international healthcare networks.
Recently, it entered a global licensing agreement with ALZpath to advance blood-based disease testing and reached administrative agreements to resolve specific infant formula litigation claims. It reported an operating margin of approximately 14% for the quarter ended June 30, 2026.
Details
Intuitive Surgical (NASDAQ:ISRG) primarily earns its revenue by manufacturing and selling robotic-assisted surgical systems, alongside the specialized disposable medical instruments, digital diagnostic accessories, and extensive technical training services required for medical facilities to operate them.
Source
Originally published at www.fool.com.